Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05536973 |
|
Recruitment Status :
Recruiting
First Posted : September 13, 2022
Last Update Posted : May 26, 2023
|
Sponsor:
Adverum Biotechnologies, Inc.
Collaborator:
Parexel
Information provided by (Responsible Party):
Adverum Biotechnologies, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Neovascular Age-related Macular Degeneration | Genetic: ADVM-022 | Phase 2 |
This Phase 2, multi-center, randomized, double-masked, parallel group study is designed to evaluate the safety, tolerability, and efficacy of a single IVT injection of ADVM-022 at one of two doses (2 × 10^11 vg/eye [2E11] or 6 × 10^10 vg/eye [6E10]) accompanied by one of four prophylactic corticosteroid treatment regimens.
Up to 72 anti-VEGF treatment-experienced study participants meeting the eligibility criteria will be randomized between the 2E11 vg/eye and 6E10 vg/eye ADVM-022 doses each with 4 prophylaxis arms for a total of 8 treatment arms, and only one eye per study participant will be selected as the study eye.
Safety, tolerability, and efficacy will be evaluated for a period of approximately 1 year from baseline.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 72 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA] |
| Actual Study Start Date : | August 23, 2022 |
| Estimated Primary Completion Date : | February 2024 |
| Estimated Study Completion Date : | February 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Age-related macular degeneration
MedlinePlus related topics:
Macular Degeneration
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dose 1
A single intravitreal injection of ADVM-022 2E11 vg/eye
|
Genetic: ADVM-022
A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens |
|
Experimental: Dose 2
A single intravitreal injection of ADVM-022 6E10 vg/eye
|
Genetic: ADVM-022
A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens |
Primary Outcome Measures :
- Severity of ocular and non-ocular adverse events [ Time Frame: From Baseline to Week 52 ]Incidence of ocular and non-ocular adverse events
- Incidence of ocular and non-ocular adverse events [ Time Frame: From Baseline to Week 52 ]Incidence of ocular and non-ocular adverse events
- Mean change in best corrected visual acuity (BCVA) from Baseline [ Time Frame: Week 52 ]BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)
Secondary Outcome Measures :
- Percentage of participants from Baseline who lose/gain at least 5, 10 or 15 letters in Best Corrected Visual Acuity (BCVA) [ Time Frame: Week 52 ]BCVA measured by ETDRS
- Mean change in BCVA from Baseline [ Time Frame: Week 26 ]BCVA measured by ETDRS
- Percentage of participants who are supplemental aflibercept injection-free [ Time Frame: Week 52 ]Supplemental anti-VEGF treatments required post therapy
- Percentage reduction in anti-VEGF injections [ Time Frame: Week 52 ]Supplemental anti-VEGF treatments required post therapy to the year prior
- Mean change in Central Subfield Thickness (CST) from Baseline [ Time Frame: Week 52 ]To evaluate the effect of ADVM-022 on CST
- Percentage of participants without CST fluctuations > 50 μm [ Time Frame: Week 52 ]To evaluate the effect of ADVM-022 on CST
- Mean number of CST fluctuations > 50 μm from Baseline [ Time Frame: Week 52 ]To evaluate the effect of ADVM-022 on CST
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female participants, ≥ 50 years of age
- Willing and able to provide written, signed informed consent for this study
- Demonstrated a meaningful response to anti-VEGF therapy
- Participants must be under active anti-VEGF treatment for wet AMD and received a minimum of 2 injections within 4 months prior to screening for the treatment of choroidal neovascularization secondary to nAMD in the study eye
- BCVA ETDRS Snellen equivalent between ≤20/25 and ≥20/320
Exclusion Criteria:
- Any condition that could affect the interpretation of results or render the participant at high risk of treatment complications in the opinion of the Investigator
- Ocular or periocular infection or intraocular inflammation in either eye within 1 month prior to or at the Randomization Visit (Day -7)
- Uncontrolled diabetes or HbA1c ≥ 7.0 %
- History or evidence of significant uncontrolled concomitant disease within 6 months of the Screening visit
- Any history of ongoing bleeding disorders or INR >3.0
- History or evidence of macular or retinal disease other than nAMD
- History or evidence of retinal detachment or retinal pigment epithelium rip/tear
- Uncontrolled ocular hypertension or glaucoma
- Prior treatment with photodynamic therapy or retinal laser for the treatment of nAMD
- Any history of vitrectomy or any other vitreoretinal surgery within 3 months prior to the Randomization Visit (Day -7)
- Prior treatment with gene therapy at any time or any non-gene therapy investigational treatment or medical device in the study eye within 3 months of the Screening Visit or 5 half-lives of the investigational medicinal product
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05536973
Contacts
| Contact: Sharri Adams-Edwards | (650) 649-1373 | LUNA-Clinops@adverum.com | |
| Contact: Adam Turpcu, PhD | (650) 649-1012 | aturpcu@adverum.com |
Locations
Show 39 study locations
Sponsors and Collaborators
Adverum Biotechnologies, Inc.
Parexel
Investigators
| Study Director: | Adam Turpcu, PhD | Adverum Biotechnologies, Inc. |
| Responsible Party: | Adverum Biotechnologies, Inc. |
| ClinicalTrials.gov Identifier: | NCT05536973 |
| Other Study ID Numbers: |
ADVM-022-11 |
| First Posted: | September 13, 2022 Key Record Dates |
| Last Update Posted: | May 26, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Adverum Biotechnologies, Inc.:
|
Aflibercept Best Corrected Visual Acuity Adverum ADVM ADVM-022 ADVM-022-11 Age-related macular degeneration Wet macular degeneration Wet AMD Choroidal neovascularization CNV |
AAV.7m8 Anti-VEGF therapy Gene therapy Blindness AAV AAV vector nAMD wAMD Eye disease Eye diseases |
Additional relevant MeSH terms:
|
Macular Degeneration Wet Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |